Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

14 avr. 2026 08h19 HE | Source: Biomerica, Inc.

Biomerica Launches inFoods® IBS in Canada Through Partnerships with Phoenix Airmid Biomedical and CanAlt Health Labs

— Represents Biomerica’s First Commercial Entry into the Canadian Market for its Precision, Diagnostic-Guided Therapy — Canada Has One of the Highest IBS Prevalence Rates in the World — an Estimated...
13 avr. 2026 18h57 HE | Source: Biomerica, Inc.

Biomerica Reports Third Quarter Fiscal 2026 Financial Results

IRVINE, Calif., April 13, 2026 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), (“Biomerica” or the “Company”) a global provider of advanced medical diagnostic and therapeutic products today...
02 avr. 2026 07h10 HE | Source: Cylinder Health

Cylinder Health launches Stool Scan to innovate and standardize one of GI care’s most subjective signals

Cylinder Health launches Stool Scan, the first clinically validated stool imaging AI built into a virtual GI care platform. Available to all members now.
19 mars 2026 07h05 HE | Source: NeurAxis, Inc.

NeurAxis Reports Strong Fourth Quarter and Full Year 2025 Financial Results

CARMEL, Ind., March 19, 2026 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for...
10 mars 2026 08h00 HE | Source: Oshi Health

New Report, “Let’s Talk Poop: Digestive Health, Denial, and the Cost of Staying Quiet,” Reveals Widespread Digestive Health Issues Accompanied By Stigma and Embarrassment

National data from Oshi Health reveals that 50% of Americans have gut issues, but a majority simply think treatable symptoms are normal.
26 févr. 2026 08h19 HE | Source: Biomerica, Inc.

Biomerica Reports Real-World Data: Nearly 60% of IBS Patients Achieved Clinically Meaningful Pain Reduction and 68% Achieved Bloating Reduction with the inFoods® IBS Therapy

Key Highlights Responder Analysis: 59.4% of patients achieved ≥30% reduction in abdominal pain; 68.1% achieved ≥30% reduction in bloating—using the FDA-recognized responder endpoint consistent...
08 janv. 2026 08h00 HE | Source: NeurAxis, Inc.

NeurAxis Achieves Major Milestone with AMA Category I CPT® Code Now in Effect, Establishing a Permanent Reimbursement Pathway

The new CPT code reflects the latest efficacious medical care available to patients, facilitating adoption and utilization.The assignment of a Category I CPT® code demonstrates a strong message to...
19 déc. 2025 08h00 HE | Source: NeurAxis, Inc.

NeurAxis Achieves Medical Coverage Policy Milestone, Expanding Access to Approximately 45 million additional Covered Lives

CARMEL, Ind., Dec. 19, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for chronic...
25 nov. 2025 08h19 HE | Source: Biomerica, Inc.

Biomerica’s inFoods® IBS Product Featured in Biotherapeutics Quarterly, a Henry Schein Publication, Highlighting a New Precision Approach for Treating IBS

Publication details large multicenter clinical trial demonstrating significant reductions in IBS symptoms through inFoods IBS guided dietary therapy IRVINE, Calif., Nov. 25, 2025 (GLOBE NEWSWIRE)...
12 nov. 2025 08h00 HE | Source: NeurAxis, Inc.

NeurAxis Announces New Medical Policy Coverage in Michigan, Adding 566,000 Covered Lives

CARMEL, Ind., Nov. 12, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for chronic...

Page suivante